enfortumab vedotin

03/15/2022 - "Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study."
01/01/2022 - "Furthermore, the efficacy of ADCs against Nectin-4 against solid tumors other than urothelial cancer has been demonstrated in preclinical studies, and clinical trials examining the effects of enfortumab vedotin are ongoing. "
01/01/2022 - "Enfortumab vedotin, an ADC against Nectin-4, has demonstrated efficacy against solid tumor malignancies. "
08/16/2020 - "Urothelial cancer is one such cancer, and clinical trials of enfortumab vedotin, a drug-conjugated anti-NECTIN4 antibody, are ongoing. "
03/01/2023 - "We evaluated patients with urothelial cancer who were treated at our institution with enfortumab vedotin (EV). "

09/01/2023 - "This study retrospectively investigated the impact of enfortumab vedotin (EV) monotherapy on the oncological outcome, safety profile, and health-related quality of life (HRQoL) in patients with metastatic urothelial carcinoma. "
01/01/2023 - "This study aimed to investigate whether Enfortumab vedotin (EV) is suitable for patients with locally advanced or metastatic urothelial carcinoma and to perform a meta-analysis of its efficacy and safety. "
01/01/2020 - "Ongoing clinical trials are aiming to further establish the role of enfortumab vedotin in urothelial carcinoma. "
01/01/2020 - "A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma."
09/01/2023 - "Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World."

01/01/2020 - "In this article, we highlight the safety and efficacy of enfortumab vedotin for patients with advanced bladder cancer, ongoing clinical trials, clinical pharmacology, and pharmacokinetics."
01/01/2023 - "Recent studies in pretreated urothelial bladder cancer have led to the approval in clinical practice of enfortumab vedotin, demonstrating better clinical efficacy compared with the standard of care. "
12/01/2023 - "In metastatic bladder cancer, enfortumab vedotin (anti-nectin 4) is positioned as the 2nd line of treatment. "
01/01/2023 - "Clinical data with enfortumab vedotin (EV) suggest that most bladder cancers overexpress NECTIN-4. "
01/01/2023 - "Enfortumab Vedotin in metastatic bladder cancer: a case report of durable clinical efficacy in a pretreated patient."

01/01/2022 - "This review highlights current knowledge on Nectin-4 in malignant tumors, the efficacy of enfortumab vedotin in clinical trials, and the prospects of Nectin-4-targeted agents against skin cancers."

10/20/2022 - "Similar to urothelial carcinoma, Nectin-4 is found in the majority of HNSCC, which clearly warrants further studies to clarify if HNSCC also respond to targeted therapy with enfortumab-vedotin. "
01/01/2020 - "*Note on key updates through December 18, 2019: 1) the US Food and Drug Administration granted accelerated approval to enfortumab vedotin-ejfv (Padcev) on December 18, 2019, bringing the total number of novel antibody therapeutics granted a first approval in either the US or EU during 2019 to 6; 2) the European Commission approved romosozumab on December 9, 2019; 3) the European Medicines Agency issued a positive opinion for brolucizumab; 4) Sesen Bio initiated a rolling biologics license application (BLA) on December 6, 2019; 5) GlaxoSmithKline submitted a BLA for belantamab mafodotin; and 6) the status of the Phase 3 study (NCT04128696) of GSK3359609, a humanized IgG4 anti-ICOS antibody, in patients with head and neck squamous cell carcinoma was updated to recruiting from not yet recruiting."